Human Induced Pluripotent Stem Cells : Clinical Significance and Applications in Neurologic Diseases

Journal of Korean Neurosurgical Society
Eun-Ah ChangSang-Dae Kim

Abstract

The generation of human induced pluripotent stem cells (iPSCs) from somatic cells using gene transfer opens new areas for precision medicine with personalized cell therapy and encourages the discovery of essential platforms for targeted drug development. iPSCs retain the genome of the donor, may regenerate indefinitely, and undergo differentiation into virtually any cell type of interest using a range of published protocols. There has been enormous interest among researchers regarding the application of iPSC technology to regenerative medicine and human disease modeling, in particular, modeling of neurologic diseases using patient-specific iPSCs. For instance, Parkinson's disease, Alzheimer's disease, and spinal cord injuries may be treated with iPSC therapy or replacement tissues obtained from iPSCs. In this review, we discuss the work so far on generation and characterization of iPSCs and focus on recent advances in the use of human iPSCs in clinical setting.

References

Nov 6, 1998·Science·J A ThomsonJ M Jones
Aug 28, 2003·Médecine sciences : M/S·Anne-Catherine FluckigerPierre Savatier
Mar 24, 2004·Trends in Biotechnology·Micha Drukker, Nissim Benvenisty
Feb 27, 2007·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Su-Chun ZhangMatthew T Pankratz
Apr 6, 2007·Journal of Neural Engineering·Ning ChenAlison Willing
Jun 8, 2007·Nature·Keisuke OkitaShinya Yamanaka
Aug 29, 2007·Nature Biotechnology·Alexander MeissnerRudolf Jaenisch
Nov 21, 2007·Cell and Tissue Research·Satoshi YamanakaKenneth R Boheler
Nov 22, 2007·Science·Junying YuJames A Thomson
Jan 30, 2008·Current Protocols in Cell Biology·Malkiel A CohenBenjamin E Reubinoff
Aug 30, 2008·Nature·Qiao ZhouDouglas A Melton
Oct 23, 2008·Cell Stem Cell·Qiao Zhou, Douglas A Melton
Mar 10, 2009·Nature Biotechnology·Joe Alper
Apr 29, 2009·Cell Stem Cell·Hongyan ZhouSheng Ding
Jan 7, 2010·The Journal of Clinical Investigation·Evangelos Kiskinis, Kevin Eggan
Mar 6, 2010·Nature Protocols·Keisuke OkitaShinya Yamanaka
Mar 1, 2009·Journal of Cardiovascular Translational Research·Dominique CharronReem Al-Daccak
Oct 15, 2010·Nature Biotechnology·Stephen Strauss
Nov 3, 2010·Journal of Molecular and Cellular Cardiology·Yoshinori Yoshida, Shinya Yamanaka
Sep 9, 2011·Human Molecular Genetics·Takuya YagiNorihiro Suzuki
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Satoshi NoriHideyuki Okano
Oct 18, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Michael G Fehlings, Reaz Vawda
Jan 20, 2012·Nature·Daisy A Robinton, George Q Daley
Jan 27, 2012·Nature·Mason A IsraelLawrence S B Goldstein
Jan 28, 2012·Lancet·Steven D SchwartzRobert Lanza
Jan 17, 2013·Current Gene Therapy·Alona O Cramer, Robert E MacLaren
Feb 2, 2013·Circulation Research·Hideyuki OkanoKyoko Miura
May 18, 2013·Stem Cell Research & Therapy·Michael W Nestor, Scott A Noggle

❮ Previous
Next ❯

Citations

Jan 18, 2020·Current Stem Cell Research & Therapy·Gaifang Wang, Maryam Farzaneh
Aug 28, 2020·World Journal of Stem Cells·Dharmendra KumarWilfried A Kues
Dec 8, 2020·Frontiers in Cellular Neuroscience·María Lacalle-AuriolesThomas M Durcan
Jan 31, 2020·Journal of Chemical Neuroanatomy·Sachchida Nand Rai, Payal Singh

❮ Previous
Next ❯

Methods Mentioned

BETA
bioprinting

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.